Apexigen

Closed (deSPAC)

Profile in progress

What it is: Inc
What it’s doing now: Merging with Brookline Capital Acquisition Corp. (BCAC) — closed (despac).
What you should know: The deal carries a $40M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Inc. Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patients immune system to combat and eradicate cancer. Sotigalimab and Apexigens other programs were discovered using Apexigens proprietary APXiMAB antibody discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.

What the company says about itself

Web research — not audited

What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-26] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The completion of the Series C financing brings the total equity raised to date by the company to $158 million." [https://www.prnewswire.com/news-releases/apexigen-completes-123-million-series-c-financing-to-advance-clinical-pipeline-301028584.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "This financing is an extension of the Company's Series C financing of $58 million, which was previously announced in August 2018, bringing the total amount raised in the Series C to $123 million." [https://www.prnewswire.com/news-releases/apexigen-completes-123-million-series-c-financing-to-advance-clinical-pipeline-301028584.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was..." [https://firstwordpharma.com/story/4634639] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "raised a total of $73 million." [https://firstwordpharma.com/story/4634639] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apexigen has raised $158.0M in total across 3 funding rounds." [https://startupintros.com/orgs/apexigen] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apexigen has raised a total of $158M over 5 funding rounds: 2 Early-Stage, 2 Late-Stage and 1 Post IPO rounds." [https://tracxn.com/d/companies/apexigen/__d4MRDEFtJp6i9HdDjKvlO1H-bRugiRjzSwv2SFFilDw/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022 and will be led by Xiaodong Yang, M.D.,Ph.D., President and Chief Executive Officer of ..." [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pyxis Oncology to Acquire Apexigen in $16M Deal" [https://www.contractpharma.com/breaking-news/pyxis-oncology-to-acquire-apexigen-in-16m-deal/] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-28] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-28] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] [WEB-INTEL 2026-08-29] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The completion of the Series C financing brings the total equity raised to date by the company to $158 million." [https://www.prnewswire.com/news-releases/apexigen-completes-123-million-series-c-financing-to-advance-clinical-pipeline-301028584.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "This financing is an extension of the Company's Series C financing of $58 million, which was previously announced in August 2018, bringing the total amount raised in the Series C to $123 million." [https://www.prnewswire.com/news-releases/apexigen-completes-123-million-series-c-financing-to-advance-clinical-pipeline-301028584.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022 and will be led by Xiaodong Yang, M.D.,Ph.D., President and Chief Executive Officer of ..." [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "raised a total of $73 million. The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was" [https://firstwordpharma.com/story/4634639] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apexigen has raised a total of $158M over 5 funding rounds: 2 Early-Stage, 2 Late-Stage and 1 Post IPO rounds." [https://tracxn.com/d/companies/apexigen/__d4MRDEFtJp6i9HdDjKvlO1H-bRugiRjzSwv2SFFilDw/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apexigen has raised $158.0M in total across 3 funding rounds." [https://startupintros.com/orgs/apexigen] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figur [WEB-INTEL 2026-09-08] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger is expected to be completed in July 2022" [https://flgpartners.com/news/apexigen-and-brookline-capital-acquisition-corp-create-publicly-listed-immuno-oncology-company-via-spac/]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Apexigen is merging with Brookline Capital Acquisition Corp. (BCAC) currently marked Closed (deSPAC).

Headline equity value	—
Minimum cash to close	$40M

Structure per SEC accession(s) 0001193125-22-100592, 0001437749-23-019040. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Apexigen going public?

Apexigen has an approved merger with the SPAC Brookline Capital Acquisition Corp. (BCAC). Deal status: Closed (deSPAC).

Does Apexigen have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.